30 July 2018
Visiongain’ has launched a new pharma report Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico
The generic drugs market has historically increased at near double-digit growth rates over the last three decades, compared to single-digit growth for the pharmaceutical market as a whole. The industry has benefited from increasing generic penetration in most major markets notable exceptions being Japan, France, Italy and Spain, where generic penetration is increasing slowly. This trend is likely to continue as falling R&D productivity begins to limit revenues for innovator companies while cost pressures encourage the growth of generic sales by volume.
The lead analyst of the report commented “The socio-economic landscape of many national and regional markets globally has been changing immensely over the last decade. This factor, coupled with the changing in the demographics of these regions will help to shape the future direction of generic drugs over the next 10 years. Population growth and ageing are expected to increase the burden of disease, especially chronic diseases such as diabetes and hypertension. This will be a major driver of the demand for generic medicines during the forecast period.”
Leading companies featured in the report include Teva, Novartis (Sandoz), Allergan, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories, Apotex
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 208 781 6953
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.